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P

apillomaviruses are a group of DNA viruses that infect the skin
and mucosal tissues of most vertebrates. More than 100 human papillomavirus (HPV) types have been identified, but far
more are presumed to exist (21). A subset of HPVs is associated
with lesions that frequently progress to cancer, and these HPVs are
classified as high-risk types. Persistent infection by high-risk
HPVs is related to 99.7% of all human cervical cancer cases (20),
other genitourinary cancers, and a growing number of oral cancers (31). Although recently developed vaccines protect individuals from the two most frequently carcinogenic HPV types, HPV16
and HPV18, they offer limited protection against other cancercausing HPVs and provide no benefit to individuals with a preexisting history of infection (13, 28, 48). The development of other
therapies to treat HPV-induced malignancy may be facilitated by
a greater understanding of the mechanisms of virally mediated
cellular transformation.
The viral E6 and E7 oncoproteins are consistently expressed in
HPV-induced cancers and are necessary to maintain malignant
cell growth (2, 4, 37, 49, 51). Repression of their transcription by
reexpression of the viral E2 regulatory protein induces rapid
growth arrest and senescence of cervical cancer cells, suggesting
that these cancer cells are addicted to E6 and E7 (33, 34). The HPV
E7 protein is a multifunctional oncoprotein that interacts with a
multitude of cellular factors (3, 6, 8, 11, 53). One of the main
activities of E7 is to induce terminally differentiated cells to enter
the cell cycle. This is accomplished in part by E7’s association with
the product of the retinoblastoma susceptibility locus (pRb) and
the related pocket protein family members p107 and p130 (25).
The interaction of E7 with pRb is essential for transformation and
abrogation of the antiproliferative signals in cervical cancer (26,
47). One of the ways in which pRb has an essential role in proliferation control is through binding to and regulating its key effectors, the E2F family of transcription factors. E2Fs coordinate the
transcription of genes that are necessary for cell cycle progression
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(10, 24, 43). During the cell cycle, as cells progress from the G1 to
S phase, the sequential phosphorylation of pRb by cyclin/cyclindependent kinase complexes causes the release of E2F from pRb
and activation of genes required for the entry into S phase (19,
41, 50).
The E7 protein contains three conserved regions (CR), termed
CR1, CR2, and CR3. CR1 and CR2 are thought to be intrinsically
disordered, while CR3 has a defined three-dimensional structure
comprised of a unique ␤1␤2␣1␤3␣2 fold (40, 45). All three regions are required for abrogation of epithelial cell quiescence and
contribute to cellular transformation (5, 26, 47). The role of the
LxCxE motif within CR2 is well established and is necessary for the
abrogation of antiproliferative signals and oncogenic transformation (26, 47). The LxCxE motif functions as a high-affinity binding
site for pRb and related family members. However, other regions
of E7 are also important for deregulating the pRb pathway, and E7
is known to exert its activity on pRb through multiple mechanisms. First, E7 binds the hypophosphorylated form of pRb in
complex with E2F and blocks the association of E2F and pRb.
Although the LxCxE motif in CR2 is necessary for interference
with pRb-E2F binding (14, 44), a requirement for both the CR1
and CR3 regions has also been established (35). Precisely how
these two regions contribute is not known. Second, E7 inactivates
a fraction of the cellular pool of pRb by targeting it for protea-
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The human papillomavirus (HPV) E7 oncoprotein binds cellular factors, preventing or retargeting their function and thereby
making the infected cell conducive for viral replication. A key target of E7 is the product of the retinoblastoma susceptibility locus (pRb). This interaction results in the release of E2F transcription factors and drives the host cell into the S phase of the cell
cycle. E7 binds pRb via a high-affinity binding site in conserved region 2 (CR2) and also targets a portion of cellular pRb for degradation via the proteasome. Evidence suggests that a secondary binding site exists in CR3, and that this interaction influences
pRb deregulation. Additionally, evidence suggests that CR3 also participates in the degradation of pRb. We have systematically
analyzed the molecular mechanisms by which CR3 contributes to deregulation of the pRb pathway by utilizing a comprehensive
series of mutations in residues predicted to be exposed on the surface of HPV16 E7 CR3. Despite differences in the ability to interact with cullin 2, all CR3 mutants degrade pRb comparably to wild-type E7. We identified two specific patches of residues on
the surface of CR3 that contribute to pRb binding independently of the high-affinity CR2 binding site. Mutants within CR3 that
affect pRb binding are less effective than the wild-type E7 in overcoming pRb-induced cell cycle arrest. This demonstrates that
the interaction between HPV16 E7 CR3 and pRb is functionally important for alteration of the cell cycle.

some-mediated degradation (9, 32, 36). Both the LxCxE motif and
CR1 are necessary for efficient reduction of pRb steady-state levels
(29, 38), while the role of CR3 has remained largely elusive. One
study has shown that small changes within CR3 do not disrupt the
pRb degradation capacity of E7 (35), but it has also been hypothesized that CR3 contributes to pRb degradation due to the observation that mutations in this region lead to reduced association
with the cullin 2 E3 ubiquitin ligase complex (36, 38). Binding of
the cullin 2 complex to E7 is mediated via its Zer1 subunit and is
currently the only known mechanism by which HPV16 E7 targets
pRb for destruction by the proteasome (36, 53). As the interaction
of cullin 2 is exclusive to HPV16 E7, the mechanism by which
other HPV E7 types degrade pRb remains unclear (36, 53). Lastly,
strong evidence has been presented that E7 CR3 contributes to
binding of pRb independently from the LxCxE motif, but the
functional significance of this interaction is unknown (15, 40, 46).
Despite the large number of biological activities that are attributed to CR3, the role of this domain of E7 in deregulating the pRb
pathway is still unclear. The study presented here was aimed at
determining the role of E7 CR3 sequences in deregulating the pRb
pathway. We examined the involvement of surface-exposed residues of HPV16 E7 CR3 in binding pRb, targeting it for degradation, and influencing pRb’s ability to induce cell cycle arrest. Although CR3 is necessary for association with the cullin 2 complex
and specific CR3 mutants affect cullin 2 interaction, none of these
mutants were impaired for pRb degradation. However, we identified two specific patches on the surface of CR3 which contribute
to pRb binding independently of the LxCxE motif in CR2. Additionally, we show for the first time that the CR3-pRb interaction is
functionally important in overcoming pRb-induced cell cycle arrest.
MATERIALS AND METHODS
Plasmids. The surface-exposed mutants of E7 were previously generated by
site-directed mutagenesis, and their construction has been described (52). For
pRb degradation assays, E7 mutations were subcloned into the BamHI and
XhoI restriction sites of a modified pCMV-Neo-Bam mammalian expression
vector. Constructs for del21-24 and C58G/C91G as well as C91G mutations
were obtained from D. Galloway (Fred Hutchinson Cancer Research Center,
University of Washington) and K. H. Vousden (National Cancer Institute at
Frederick, Frederick, MD), respectively, and subcloned as necessary. For degradation assays carried out in H1299 cells, full-length E7 mutants were subcloned into the pCMV-Neo-Bam expression vector with a tandem N-terminal flag-hemagglutinin tag using BamHI and XhoI restriction sites. For
expression in yeast, full-length E7 was cloned into a modified pJG4-5⫹ vector
(Clontech) using EcoRI and SalI or XhoI sites (52) or, in the case of the
HPV16 E7 CR3 region, using PvuII and XhoI. HPV6, HPV11, and HPV18
CR3 regions were PCR amplified using the following primers: HPV6-F, CG
AATTCCGAAGTGGACGGACAAGATTCA; HPV6-R, GATCCTCGAG
TTAGGTCTTCGGTGCGCAG; HPV11-F, CGAATTCAAGGTGGACAA
ACAAGACGCA; HPV11-R, TATGTCGACTTATGGTTTTGGTGCGCA
GATGGG; HPV18-F, CGAATTCGATGGAGTTAATCATCAACAT; and
HPV18-R, CCGCTCGAGTTACTGCTGGGATGC. PCR products were
cloned into EcoRI and XhoI or SalI sites of the modified pJG4-5⫹. For
expression of green fluorescent protein (GFP)-fused constructs, either
full-length or PCR-amplified fragments of E7 were cloned into EcoRI and
XbaI sites of pCAN-myc-EGFP. Either the wild-type or mutant CR3 region of HPV16 E7 (residues 39 to 98) was subcloned from their respective
pJG4-5⫹ plasmid into pCAN-myc-EGFP. Alternatively, fragments of residues 1 to 39, 1 to 57, and 39 to 58 were first PCR amplified using the
following primers: 1-39 F, GTCGAATTCATGCATGGAGATACACCTA
CATTGC; 1-39 R, ATTATCTAGAATCTCGAGTTAATCTATTTCATCC
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TCCTC; 1-57 F, CGAATTCGTAATCATGCATGGAGATAC; 1-57 R, CC
TCTCGAGCTAAAAGGTTACAATATTGTAATG; 39-58 F, ATTAGAAT
TCGATGGTCCAGCTGGACAA; and 39-58 R, ATTATCTACAATCTCG
AGTTAACAAAAGGTTACAATATT. They were subsequently cloned
into the EcoRI and XbaI sites of pCAN-myc-EGFP. For recombinant protein production and purification, the CR3 region of each E7 construct was
cloned into the pGEX4T1 (Invitrogen) vector that was modified to contain the tobacco etch virus (TEV) protease recognition sequence between
the glutathione S-transferase (GST) tag and the protein of interest. The
pCMV-pRb, pGEX4T1-pRbC, and pScodon-pRbABC constructs were
previously described (12, 22, 23). Residues 379 to 792 of pRb were PCR
amplified and cloned into the BamHI site of pGEX4T1. pBB14-Us9-EGFP
has been described previously (39). pCMV-HA-cullin 2 was a gift from P.
Branton (McGill University, Montreal, Canada); pcDNA3-HA-pRb was a
gift from J. DeCaprio (Dana Farber Cancer Institute, Harvard Medical
School, Boston, MA), and pcDNA3-His-␤gal has been described previously (42). PSH1834 reporter plasmid for yeast two-hybrid analyses was
recovered from the EGY48 yeast strain and contains eight operator sequences that respond to LexA. pCMV-HA-p21 plasmid has been described previously (16).
Cell culture, transfection, and pRb degradation assay. Human
Saos2, HT1080, and H1299 cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum
and penicillin-streptomycin (100 U/ml). H1299 control and cullin 2
knockdown (KD) cells have been previously described (17, 18) and were
maintained supplemented with 1 g/ml of puromycin. For pRb degradation assays, Saos2 cells were seeded into 6-well plates at 3 ⫻ 105 cells per
well and transfected 24 h later with 2 g of pRb with or without 0.2 g of
E7 expression plasmid and with 0.1 g of green fluorescent protein (GFP)
or ␤-galactosidase (␤-gal) expression plasmid as a control using FugeneHD (Roche) according to the instructions provided by the manufacturer, unless otherwise noted. The amount of plasmid DNA was balanced
with empty pCMV vector where necessary. The amounts of pRb, GFP,
and actin were assessed by Western blotting 48 h posttransfection. Assessment of pRb degradation in H1299 control or cullin 2 KD cells was carried
out similarly, where 0.2 g of HA-pRb expression plasmid was cotransfected with an increasing amount of wild-type or mutant Flag-HA-tagged
E7-expressing plasmid (20, 200, or 2,000 ng) using X-tremeGENE HP
(Roche). The amounts of pRb, E7, and actin were determined 24 h posttransfection by Western blotting. For coimmunoprecipitation experiments, HT1080 cells were seeded into 10-cm plates at 2 ⫻ 106 cells per
plate and transfected 24 h later with 8 g of total DNA with X-tremeGENE
HP (Roche) according to the manufacturer’s instructions. Twenty-four h
posttransfection cells were collected for coimmunoprecipitation experiments. For cycloheximide treatment experiments, HT1080 cells were
seeded into 6-well plates 24 h before transfection. For each mutant, the
cells were transfected with 2 g of E7 pCMV-Neo-Bam expression plasmid along with 0.1 g of GFP expression plasmid using X-tremeGENE
HP. At 24 h posttransfection, the cells were treated with 0.5 g/l cycloheximide for 0, 15, 30, and 60 min.
Antibodies. The following antibodies were used: rat anti-hemagglutinin
(anti-HA) (Roche) at 1:2,000 and rabbit anti-glucose-6-phosphate dehydrogenase (anti-G6PD), used as a loading control for yeast samples, at
1:80,000 (Sigma). For detection of pRb in the degradation assay, mouse
anti-pRb (G3-245; BD Pharmingen) was used at 1:500 or mouse anti-pRb
hybridoma lysate (clone C36) at 1:4. GFP was detected using rabbit antiGFP (Living Colors; Clontech) at 1:2,000. Cullin 2 was detected using
rabbit polyclonal anti-cul2 antibody at 1:10,000 (Bethyl Laboratories).
Myc-tagged constructs were detected with mouse anti-myc hybridoma
lysate (clone 9E10) used at 1:200. Mouse anti-␤-gal (Promega) and rabbit
anti-actin (Sigma) were used at 1:2,000. Mouse anti-E7 (8C9 clone; Invitrogen) was used at 1:200. Horseradish peroxidase (HRP)-conjugated goat
anti-rabbit (Jackson Laboratories), goat anti-rat (Pierce), and rabbit antimouse (Jackson Laboratories) secondary antibodies were used.
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HPV16 E7 CR3 Deregulates pRb Function
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FIG 1 Schematic representation of HPV16 E7 and the position of mutations
targeting residues within CR3. The conserved regions (CR1, CR2, and CR3)
are depicted as boxes. The amino acid sequences of CR3 and the mutations
used in this study are indicated. Also indicated are del21-24, which removes
the LxCxE motif in CR2 of E7, and the C58G/C91G mutant, which targets
zinc-coordinating cysteine residues within CR3.

plasmids), with FugeneHD (Roche). Twenty-four h posttransfection, cells
were transferred to either 10- or 15-cm dishes (depending on the size of
the original dish) using phosphate-buffered saline supplemented with 10
mM EDTA (PBS-EDTA). Forty-eight h after the transfer to a new dish,
cells were collected with PBS-EDAT solution and washed once with PBS.
Cell pellets were resuspended in 300 l of 50% fetal bovine serum (FBS)
solution (in PBS) and fixed by dropwise addition of 900 l of ice-cold 70%
ethanol. Samples were incubated on ice for at least 2 h and then washed
two times with PBS. Cells were resuspended in and stained with 300 l of
propidium iodide staining solution (1% FBS, 10 g/ml propidium iodide,
0.25 mg/ml RNase A in PBS). Cell cycle data were collected by flow cytometry on a FACSCalibur (BD Biosciences). DNA content was determined based on propidium iodide staining. Data were analyzed using
FlowJo software, and the percentage of cells in G1 phase was determined
using the Watson model.

RESULTS

CR3 mutations. To examine the role that HPV16 E7 CR3 plays in
pRb deregulation, we utilized the panel of putative surface-exposed mutants within CR3, here referred to as the surface-exposed
mutants. These have been previously described by our group (52).
Briefly, these mutations target residues whose side chains are predicted to be at least 25% surface exposed but not those that would
participate in stabilizing the structural features of E7 (40, 45, 52).
Hence, these mutations were constructed with the dual aims of
preserving the structure of the CR3 region while disrupting the
interaction surfaces available for cellular targets. In total we included in these studies 19 point mutants, one double mutant, and
one mutant targeting the last three amino acids of CR3 (Fig. 1). As
controls, we also utilized the deletion mutant, del21-24, which
removes the LxCxE motif in CR2, and the C58G/C91G mutant,
which targets two critical zinc-coordinating cysteines in CR3 and
is thought to grossly perturb the folded structure of this region
of E7.
Contribution of HPV16 E7 CR3 to pRb degradation. The LxCxE motif and certain residues within CR1 of E7 were previously
shown to be important for pRb degradation (32, 35). Other studies have also examined the role of CR3 and have found no contribution of any single residue to pRb degradation (7, 35). However,
another study has shown that specific residues within CR3 contribute to cullin 2 complex binding, currently the exclusive mechanism known to be used by HPV16 E7 to degrade pRb (36). These
findings led us to reexamine the role of CR3 in pRb degradation.
Our first aim was to map the surface of CR3 which is required for
pRb degradation utilizing the panel of surface-exposed mutants.
Our approach was to test full-length wild-type E7 or E7 mutants
for their ability to degrade pRb exogenously expressed in pRb-null
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Coimmunoprecipitation and Western blot analysis. Cells were
transfected in a 1:1 ratio of the myc-GFP fusion and hemagglutinin (HA)tagged binding partner (cullin 2, pRb, or p21). Cells were harvested at 24
h posttransfection by scraping and washed once with 1⫻ phosphate-buffered saline (PBS). Cells were lysed in NP-40 (50 mM Tris, pH 7.8, 150 mM
NaCl, 0.1% NP-40) lysis buffer supplemented with 1⫻ mammalian protease inhibitor cocktail (Sigma). Typically, 1 mg of cell lysate was mixed
with 100 l of anti-myc hybridoma (clone 9E10) or 1 l of anti-GFP
antibody and 100 l of 10% slurry of protein A-Sepharose resin (Sigma)
and incubated at 4°C for 1 to 2 h with nutating. Immunoprecipitates were
washed three times with lysis buffer, resuspended in 2⫻ lithium dodecyl
sulfate (LDS) sample buffer, and boiled for 5 min. Samples were then
separated by SDS-PAGE, transferred to a polyvinylidene difluoride membrane (GE), and blocked in 5% nonfat milk in Tris-buffered saline-Tween 20.
Western blot analyses were carried out with mouse anti-myc hybridoma
clone (9E10) or rat monoclonal anti-HA (clone 3F10; Roche).
Yeast two-hybrid assay. Yeast two-hybrid analysis was performed in
strain W303-1a (MATa leu2-3,112 his3-11,15 trp1-1 ura3-1 ade2-1, can1100). Standard yeast culture medium was prepared using previously described methods (1). Yeast transformation was carried out using a modified lithium acetate procedure (30). Yeast cells were transformed with
the reporter plasmid and pRb and E7 expression plasmids and then
plated on selective medium plates and grown at 30°C for 2 to 4 days.
The method for assaying ␤-galactosidase activity in yeast has been
described previously (1).
GST pulldown assays. Recombinant GST-tagged E7 CR3 (residues 39
to 98) and GST-tagged fragments of pRb (pRb-AB and pRb-C) were expressed in and purified from the BL21-RIL strain of Escherichia coli and
pRbABC from the BL21-Gold strain per protocols provided by the affinity
resin manufacturer (Amersham). For GST pulldown experiments with
GST-CR3, Saos2 cells were transfected with pRb expression plasmid and
lysates prepared 48 h posttransfection in NP-40 lysis buffer. Approximately 400 g of Saos2 extract was used per reaction and mixed with an
increasing amount of GST-CR3, 600 l of NP-40 lysis buffer, and 20 l of
50% glutathione Sepharose. Reaction mixtures were incubated at 4°C for
1 h and then washed two times with the lysis buffer. Samples were resuspended in 2⫻ LDS sample buffer, boiled for 5 min, then separated by SDSPAGE and examined by Western blotting for the amount of associated pRb.
For GST pulldown assay with purified recombinant GST-pRbABC, -pRbAB,
or -pRbC, HT1080 cells were transfected with myc-GFP-E7 39-98 expression
plasmid. Lysates were prepared 24 h posttransfection in NP-40 lysis buffer.
Approximately 1 mg of lysate was mixed with an increasing amount of GSTpRb fragment and 20 l of 50% glutathione Sepharose. Reaction mixtures
were incubated and samples processed as indicated above. Western blot analysis was used to assess the amount of associated myc-GFP-E7 39-98 by blotting with anti-myc.
In vitro pRb binding assay. To obtain untagged E7 CR3 (residues 39
to 98), purified recombinant GST-tagged wild-type E7 CR3 and mutants
were incubated with ⬃0.2 g/ml TEV protease overnight at 4°C. The
purified protein concentration was determined using the Bio-Rad assay
and was verified by running 0.5 g of purified protein on a gel and silver
staining (SilverQuest staining kit; Invitrogen) prior to using the samples
in the assay. The ability of E7 CR3 to associate with GST-pRbABC was
assessed at protein concentrations well below saturation levels (see Fig.
7A). Briefly, 0.6 M E7 CR3 (residues 39 to 98) was incubated with 0.3
M GST-pRbABC at room temperature for 1 h in a total volume of 300 l
of phosphate buffer (20 mM phosphate, pH 7.0, 200 mM NaCl, 1% Tween
20, 2 mM dithiothreitol) and 20 l of 50% glutathione Sepharose. Samples were washed three times with phosphate buffer, boiled in 2⫻ LDS
sample buffer for 5 min, and separated by SDS-PAGE. Gels were silver
stained to determine the amount of associated E7 CR3.
Cell cycle analysis. A total of 6 ⫻ 105 or 1 ⫻ 106 Saos2 cells were
seeded into 6- or 10-cm dishes, respectively. Cells were transfected with
1.5 g of each Us9-EGFP expression plasmid (membrane-bound GFP)
and pRb, as well as 3 g of untagged, full-length E7 (pCMV-Neo-Bam
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FIG 2 All E7 CR3 mutants retain the ability to degrade pRb. (A) Dose-dependent degradation of pRb by wild-type E7 in Saos2 osteosarcoma cells. Saos2 cells

Saos2 osteosarcoma cells. Cotransfection of pRb with increasing
amounts of wild-type E7 led to a dose-dependent decrease in pRb
levels (Fig. 2A). As expected, cotransfection of the del21-24 E7
mutant, which removes the high-affinity LxCxE site, did not reduce pRb levels. However, all 21 of the CR3 mutants that we tested
retained the ability to degrade pRb comparably to wild-type E7
under nonsaturating conditions (Fig. 2B).
Contribution of HPV16 E7 CR3 to cullin 2 binding and the
role of cullin 2 in E7-mediated pRb degradation. The findings
described above led us to question whether the pRb degradation
phenotypes observed could be due to the fact that each of these
surface-exposed mutants maintains the ability to associate with
the cullin 2 complex. This seemed unlikely, as others previously
showed that mutations CVQ68-70AAA, del79-83, and C91S lose
the ability to associate with the cullin 2 complex (36). Before testing the individual mutants for interaction with cullin 2, we first
determined which portions of E7 mediated binding using GFP
fused to fragments of E7 corresponding to residues 1 to 39 (CR1
and CR2), 39 to 58 (N terminus of CR3), and 39 to 98 (CR3). In
coimmunoprecipitation experiments, neither residues 1 to 39 nor
39 to 58 of E7 could interact with the cullin 2 complex on their
own. In contrast, residues 39 to 98 (CR3) of E7 were necessary and
sufficient for this interaction (Fig. 3A). To test the properties of
the surface-exposed mutants for cullin 2 binding, we expressed the
entire panel in the context of the residue 39 to 98 fragment fused to
GFP. In coimmunoprecipitation experiments with coexpressed
HA-cullin 2, all mutants retained at least some ability to associate
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with this complex (Fig. 3B). However, mutants such as N53D,
V55T, and S63D had a substantially reduced capacity to associate
with the cullin 2 complex. Nonetheless, as described above, all of
these mutations retained the ability to target pRb for degradation.
These results suggest that either the relatively weak interaction
with cullin 2 is sufficient for pRb degradation or that other, as-yet
unidentified mechanisms are utilized for the degradation process.
In addition to assessing the ability of our panel of surface-exposed
mutants to bind the cullin 2 complex, we also included in these
experiments the C58G/C91G mutant, which abrogates zinc coordination within CR3 and presumably disrupts proper folding of
this domain (Fig. 3B). A similar mutation, C91S, in the context of
full-length E7 was previously shown to disrupt cullin 2 binding
(36). Unexpectedly, we found that C58G/C91G associated with
cullin 2 at least as well as wild-type E7 residues 39 to 98 (Fig. 3B).
When tested for the ability to target pRb for degradation in the
Saos2 cell assay, the C58G/C91G mutant in the context of fulllength E7 degraded pRb in a dose-dependent manner that was
indistinguishable from wild-type E7 (Fig. 3C). The C91G mutation was similarly tested and behaved identically to C58G/C91G
(data not shown). These findings suggest that both cullin 2 binding and pRb degradation function independently of correct folding of CR3.
To further study to role of cullin 2 in the pRb degradation
process, we compared the ability of four E7 mutants identified to
have reduced association with cullin 2 (N53D, V55T, R66E, and
T72D) to degrade pRb in H1299 cells in which cullin 2 was stably
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were transfected with 1 g of pRb expression plasmid, 0.1 g GFP expression plasmid, and the indicated amount of wild-type E7 expression plasmid; 48 h
posttransfection cells were collected and samples analyzed by Western blotting for pRb, GFP, and actin levels. (B) pRb degradation by E7 mutants. Full-length
wild-type E7 or the indicated mutants were transfected with pRb and GFP expression plasmids at a 1:10 ratio of E7 to pRb, and at 48 h posttransfection levels of
pRb were analyzed. The blot is a representative image; the bar graphs represent quantified pRb levels normalized to GFP and actin levels. The relative pRb levels
are representative of five independent experiments.

FIG 3 Contribution of cullin 2 complex to E7-induced pRb degradation. (A) CR3 of E7 is necessary and sufficient to bind cullin 2. HT1080 cells were transfected
with an equal ratio of hemagglutinin (HA)-tagged cullin 2 expression plasmid to either myc-GFP or myc-GFP-fused E7 fragment (as indicated). Twenty-four h
posttransfection, cell lysates were subjected to immunoprecipitation (IP) with anti-myc antibody, followed by Western blotting for cullin 2 with anti-HA
antibody. (B) Cullin 2 binding capacity of CR3 mutants. HT1080 cells were cotransfected with HA-tagged cullin 2 and either myc-GFP or myc-GFP-fused E7
39-98 (wild type or indicated mutant). Coimmunoprecipitation was carried out as described above. (C) The C58G/C91G mutant retains the ability to degrade
pRb. Saos2 cells were transfected with 1 g pRb, 0.1 g ␤-galactosidase, and the indicated amounts of full-length wild-type or C58G/C91G mutant E7. Samples
were collected 48 h posttransfection, and the steady-state levels of pRb were analyzed by Western blotting. %pRb indicates the relative amount of remaining pRb
in each lane. (D) Cullin 2 levels in H1299 control and H1299 cullin 2 knockdown (KD) cells. The levels of endogenous cullin 2 present in H1299 control and
H1299 cullin 2 KD cells were analyzed using anti-cul2 antibody. (B) Dependence of E7 on cullin 2 for pRb degradation. pRb degradation assays were conducted
in cullin 2 KD and control cells for indicated E7 mutants, as described in Materials and Methods.

knocked down (Fig. 3E). Each mutant degraded pRb in cullin 2
knockdown cells similarly to control cells, further suggesting that
E7 is utilizing a cullin 2-independent mechanism to degrade pRb.
CR3 binds pRb independently of the LxCxE motif in vitro
and in vivo. Several reports have suggested that CR3 contributes
to deregulation of pRb function by providing a secondary loweraffinity binding site. For example, full-length E7 binds pRb more
strongly than mutants retaining the LxCxE motif but lacking CR3
(46). More recently, it was demonstrated in two independent
studies that CR3 binds pRb in vitro (15, 45). We first confirmed
that purified GST-CR3 of E7 was sufficient to independently pull
down pRb from cell lysates in a dose-dependent manner (Fig. 4A).
Utilizing the reciprocal approach, we also demonstrated that a
recombinant large pocket of pRb (GST-pRbABC) could associate
with GFP-CR3 from cell lysates obtained by overexpressing GFPCR3 in HT1080 cells (Fig. 4B). Additionally, the small pocket of
pRb (pRbAB) was sufficient for this interaction, consistent with a
previous report (15). In contrast, the C terminus of pRb (pRbC)
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was not sufficient to interact with CR3 of E7. As CR3 has never
been reported to interact with pRb in vivo, we examined the ability
of GFP-CR3 to coimmunoprecipitate HA-pRb. As expected, an
N-terminal fragment of E7 (residues 1 to 57, containing the highaffinity LxCxE binding site for pRb) was found to associate
strongly with pRb by coimmunoprecipitation (Fig. 5A). Importantly, the CR3 region of E7 (residues 39 to 98) was also sufficient
to coimmunoprecipitate pRb, albeit at a substantially lower level
than the full-length E7 protein or the LxCxE-containing N-terminal fragment. Yeast two-hybrid analysis utilizing E7 fragments
spanning residues 1 to 57 or 39 to 98 as prey and full-length pRb as
bait showed that CR3 also interacted with pRb independently of
the N terminus. In these assays, residues 39 to 98 bound pRb with
approximately 30% of the activity observed with full-length E7
(Fig. 5B).
CR3s from other HPV types also interact with pRb. Utilizing
coimmunoprecipitation experiments, we determined that fulllength E7 from the high-risk HPV18 and low-risk HPV6 and
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HPV11 also associated with pRb in mammalian cells cotransfected with E7 and pRb (Fig. 5C) or utilizing endogenous pRb
(data not shown). This was expected, as each of the E7 proteins
contains a high-affinity LxCxE motif. We next tested whether the
E7 CR3 regions from other HPV types could interact in vivo with
pRb independently of the LxCxE binding site in CR2. In a yeast
two-hybrid analysis, low-risk HPV6 and HPV11 E7 CR3 regions
also interacted with pRb, whereas little or no activity was detected for
the high-risk HPV18 CR3 (Fig. 5D). Similar to the coimmunoprecipitation experiments from mammalian cells, each of the full-length
E7 proteins was also able to bind pRb in the yeast two-hybrid assay.
These results indicate that while all of the E7 proteins tested could
bind pRb, the ability to interact with pRb via CR3 is not a universal
property of all E7 proteins.
Mapping the binding surface for pRb in CR3. We initially
used the yeast two-hybrid system as a rapid method to identify
candidate residues from HPV16 E7 that are involved in binding
pRb. We cloned our panel of mutants into a yeast two-hybrid prey
vector as fragments expressing only residues 39 to 98 and assessed
their capacity to bind pRb. With this approach, we identified a
number of mutants with statistically significant differences in pRb
binding. Specifically, V55T, F57A, R66E, M84S, and I93T were
increased and Y52A, N53D, C59S, S63D, T64D, T72D, R77E, and
G85A were decreased. The most significant increase in binding
was observed for R66E, which displayed 10 times higher ␤-galactosidase activity than the wild-type CR3. In contrast, Y52A, N53D,
C59S, and G85A all showed more than 50% reductions in activity
(Fig. 6B). It should be noted that for the yeast two-hybrid analysis,
CR3 mutants were previously assessed for any autoactivation po-
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tential (52). Although R66E had greatly increased pRb binding
potential in the yeast two-hybrid analysis, this was not due to
enhanced autoactivation. To rule out the possibility that differential expression played a role in the observed changes in binding
capacities, we tested the majority of CR3 mutants which displayed
increased or decreased binding (mutations with P ⱕ 0.05) for
expression in yeast cells. All mutants with decreased binding capacity were expressed comparably to the wild type except for
S63D, which was expressed at a slightly lower level (Fig. 6C). Similarly, mutants with increased binding for pRb were expressed
comparably to the wild type, with the possibility that the slight
increase in binding seen with the D62K and I93T mutants could be
the result of increased expression. It should be noted that fulllength E7 wild type or mutants were also assessed for the capacity
to associate with pRb in a yeast two-hybrid analysis (Fig. 6A).
With this approach, we found that none of the mutants exhibited
a substantially reduced ability to associate with pRb, suggesting
that defects in binding via CR3 are masked by the high-affinity
pRb binding site within CR2.
Confirmation of the pRb binding properties of E7 CR3 mutants in vitro. Our initial analysis using the yeast two-hybrid system identified a number of residues that appeared to contribute to
the interaction of CR3 with pRb. Interestingly, most of these residues map to two independent patches on the surface of CR3.
Specifically, residues Y52, N53, V55, F57, C59, S63, T64, R66, and
T72 map to one region, referred to as patch 1; residues R77, M84,
and G85 map to a second region, referred to as patch 2. However,
results from yeast two-hybrid assays may be influenced by the
presence of additional factors in yeast. In order to conclusively
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FIG 4 E7 CR3 interacts with pRb independently of the LxCxE motif in vitro. (A) GST-CR3 associates with pRb from cell lysates. Increasing amounts of GST-CR3
(residues 39 to 98) were incubated with ⬃400 g of Saos2 cell lysate (previously transfected with pRb expression plasmid) and analyzed for the amount of
associated pRb via Western blotting. (B) GFP-CR3 (residues 39 to 98) associates with the large and small pockets of pRb. HT1080 cells were transfected with
myc-GFP or myc-GFP-fused E7 39-98. Twenty-four h posttransfection, cell lysates were prepared and ⬃1 mg was used in each GST pulldown reaction. Five g
of GST was incubated with 1 mg of myc-GFP-E7 39-98 lysate as a control. Five g of GST-pRbABC (large pocket), GST-pRbAB (small pocket), and GST-pRbC
(C terminus of pRb) was incubated with 1 mg of myc-GFP lysate as a control. Increasing amounts of GST-pRb fragments (0.5, 1, or 5 g) were incubated with
1 mg of myc-GFP-E7 39-98 lysate. Samples were washed and then analyzed by Western blotting for the amount of associated myc-GFP-E7 39-98. The bottom
panel is the Ponceau stain of the membrane, illustrating the input levels of GST-pRb fragments. The left side of the Ponceau stain indicates the position and size
of the ladder in kDa.

HPV16 E7 CR3 Deregulates pRb Function

(A) E7 CR3 interacts with pRb in vivo. HT1080 cells were cotransfected with
equal amounts of HA-tagged pRb and myc-GFP or myc-GFP-E7 fragments.
Twenty-four h posttransfection, cell lysates were prepared and subjected to
immunoprecipitation with anti-myc antibody, followed by Western blotting
for HA-pRb. (B) HPV16 E7 CR3 interacts with pRb in a yeast two-hybrid
assay. Yeast cells were transformed with either empty vector, full-length E7, or
the two indicated E7 fragments as prey proteins, along with pRb as bait and a
LexA-responsive ␤-galactosidase reporter plasmid. Following transformation,
yeast cells were analyzed for ␤-galactosidase activity. Data are presented as
percent binding relative to that of full-length E7. (C) E7 proteins from other
HPV types also associate with pRb. HT1080 cells were cotransfected with equal
amounts of HA-tagged pRb and myc-GFP or myc-GFP-E7 from HPV16,
HPV18, HPV6, or HPV11. Twenty-four h posttransfection, immunoprecipitation and Western blotting were carried out as described above. (D) CR3
regions from other HPV types also associate with pRb independently from the
LxCxE motif. The C-terminal portions of HPV16, HPV18, HPV11, and HPV6
were tested for the ability to associate with pRb similarly to what was described
for panel B. Data are represented as experimentally determined ␤-galactosidase activity.

determine if the identified residues contribute to pRb binding, we
set up an in vitro GST pulldown assay utilizing the affinity-purified
recombinant GST-fused large pocket of pRb and increasing molar amounts of purified wild-type CR3 (E7 residues 39 to 98). In
this assay, CR3 associated with pRb in a dose-dependent manner (Fig. 7A). This analysis established appropriate protein
concentrations for the assay, ensuring that the reactions were
carried out at levels of CR3 below saturation. For all subsequent experiments, GST pulldown assays were set up with 0.3
M pRbABC and a 2-fold molar excess of wild-type or mutant
CR3 (0.6 M).
To confirm the contribution of patch 1 to pRb binding, we
focused on mutants of E7 with the most significantly altered
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FIG 6 Identification of CR3 residues involved in binding pRb using the yeast
two-hybrid system. (A) Yeast two-hybrid analysis of the binding capabilities of
full-length E7 mutants and pRb. Yeast cells were transformed with full-length
pRb expression plasmid as bait and full-length wild-type or mutant E7 as prey,
in addition to the LexA-responsive ␤-galactosidase reporter plasmid. Data are
shown relative to wild-type E7 and are representative of four independent
experiments. (B) Yeast two-hybrid analysis of the binding capabilities of E7
CR3 mutants. Yeast cells were transformed with full-length pRb expression
plasmid as bait and wild-type or mutant fragment of E7 spanning residues 39
to 98, in addition to the LexA-responsive ␤-galactosidase reporter plasmid.
Data are represented relative to wild-type E7 39-98. **, P ⱕ 0.01; *, P ⱕ 0.05.
(C) Expression level of E7 CR3 mutants in yeast cells. The same yeast cultures
used for the analysis of the pRb-CR3 interaction were also analyzed by Western
blotting for E7 CR3 protein expression levels.

binding (P ⱕ 0.01) as determined by the yeast two-hybrid system (Fig. 6B). These included Y52A, N53D, V55T, F57A, C59S,
S63D, T64D, R66E, and T72D. Of these mutants, all but R66E bound
pRb at reduced levels in vitro (Fig. 7C and D). Taken together, the
data from these two independent types of analyses clearly indicate
that patch 1 contributes to pRb binding by CR3.
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Patch 2 overlaps residues previously reported to contribute to
pRb interaction, including R77, E80, and D81 (45). In agreement,
E80K/D81K retained only ⬃25% of the binding capacity for the
large pocket of pRb in our in vitro tests. In contrast, R77E showed
a substantial increase in pRb binding and G85A bound comparably to the wild type (Fig. 7C and D). These data suggest that negative charges present within patch 2 contribute to pRb interaction,
as previously proposed (45).
The CR3-pRb interaction is important for E7 to overcome
pRb-induced cell cycle arrest. Although all surface-exposed mutants of E7 CR3 can target pRb for degradation, our data demonstrate that specific residues contribute to pRb binding. To determine the functional significance of this interaction, we assessed
patch 1 and patch 2 mutants for their ability to overcome cell cycle
arrest induced by reintroduction of pRb into pRb-null Saos2 cells.
Reintroduction of pRb into Saos2 cells results in ⬃80% of cells
arresting in the G1 phase of the cell cycle (Fig. 8A). Coexpression
of full-length wild-type E7 reverses this arrest, with ⬃40% of the
cells remaining in G1. The change in percentage of cells in G1 in
the presence or absence of wild-type E7 was normalized to 100%
(Fig. 8A). Although the LxCxE deletion mutant del21-24 was impaired for inducing G1 exit, it still retained 27% of wild-type activity. We tested all CR3 mutants that were assessed for pRb binding in vitro for their ability to overcome this pRb-induced cell cycle
arrest. Of those mutants located within patch 1, we found that all
except C59S, R66E, and T72D had a significantly reduced ability
to overcome cell cycle arrest. Their activity ranged from 60 to 77%
of that of wild-type E7. C59S and T72D showed a modest decrease
in the ability to bind pRb in vitro but behaved similarly to wild-
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type E7 in their ability to overcome cell cycle arrest. R66E retained
pRb binding in both the yeast two-hybrid and the in vitro studies
and overcame cell cycle arrest, similar to wild-type E7. This finding is consistent with a previous analysis of R66A in similar functional assays (35). Of the patch 2 mutants, R77E behaved like
wild-type E7, but G85A and E80K/D81K retained only about 60%
of wild-type capacity to overcome the G1 arrest. The reduced ability of
the mutants to overcome the pRb-induced cell cycle arrest was not
related to a reduction in their stability (Fig. 8B). We also tested selected mutants for their ability to interact with p21Cip1/WAF1 by coimmunoprecipitation, as this regulator of G1 exit has previously been
reported to interact with HPV16 E7 CR3 (27). However, no correlation was apparent between binding p21Cip1/WAF1 and ability to overcome a pRb-induced cell cycle arrest (Fig. 9). Taken together, CR3
mutants with reduced ability to bind pRb typically were less able to
overcome a pRb-induced cell cycle arrest.
DISCUSSION

Although the role of HPV E7 in cellular transformation and cancer progression has been extensively studied, we still do not fully
understand how E7 deregulates one of its most vital interacting
partners, the retinoblastoma tumor suppressor (pRb). Precise assessment of E7-pRb protein interactions appears fundamental to
understanding virally mediated subversion of cell cycle control
and may allow novel shared features of viral and cellular pRb
protein interaction partners to be uncovered. The objective of this
study was to more precisely determine the role of E7 CR3 sequences in deregulating the pRb pathway.
For these studies, we utilized an extensive panel of surface-
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FIG 7 Mapping the pRb binding surface on CR3 in vitro. (A) CR3 associates with the large pocket of pRb (pRbABC) in a dose-dependent manner. GST-pRbABC
(0.3 M) was incubated with increasing amounts of purified CR3 (residues 39 to 98), and the amount of associated CR3 was determined by silver staining. (B)
Representative gel image of CR3-pRb binding as quantified for panel C. (C) Patch 1 residues most significantly contribute to pRb binding. Purified wild-type CR3
or the indicated mutant was assessed for the ability to bind pRb in a GST pulldown assay using 0.3 M GST-pRbABC and 0.6 M CR3. Data are presented relative
to wild-type protein and are representative of a minimum of three independent assays. **, P ⱕ 0.001; *, P ⫽ 0.032. (D) Based on the in vitro analysis, patch 1 and
patch 2 residues significantly contributed to pRb binding. Colored in blue are patch 1 residues Y52, N53, V55, F57, C59, S63, T64, and T72, as well as R77, E80,
and D81 within patch 2.

HPV16 E7 CR3 Deregulates pRb Function

FIG 9 Association of E7 mutants with p21Cip1/WAF1. HT1080 cells were

FIG 8 CR3-pRb interaction is functionally important for overcoming cell
cycle arrest. (A) Mutants with reduced capacity to associate with pRb via CR3
have defects in overcoming cell cycle arrest. Mutants analyzed for pRb binding
in vitro were also assessed for their ability to overcome cell cycle arrest induced
by reexpression of wild-type pRb in Saos2 cells. The percentage of cells in G1
phase of the cell cycle was determined by flow cytometry. Control cells represent the normally cycling Saos2 population. Saos2 cells expressing pRb only
but not E7 are labeled as pRb only. For all other samples, cells express pRb and
either the full-length wild-type or indicated mutant E7 protein. Data are representative of a minimum of three independent experiments. ***, P ⱕ 0.001;
**, P ⱕ 0.01; and *, P ⱕ 0.05 relative to the wild-type E7 sample. The relative
activity of E7 mutants in overcoming cell cycle arrest was calculated and is
indicated below the bar graph. (B) Analysis of E7 mutant stability. HT1080
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exposed mutants of HPV16 E7 CR3, which target residues that are
accessible for interaction with cellular partners (Fig. 1). Unlike
previous work, we avoided using deletion mutants or mutants
which target highly conserved, structurally important hydrophobic residues of E7 CR3 (52). This approach allowed us to examine
the role of each individual residue on the surface of CR3 in deregulating pRb function. Utilizing this panel of mutants, we first
tested whether any of the introduced changes on the surface of E7
CR3 reduced its capacity to target pRb for degradation. Unexpectedly, the entire panel of 21 surface-exposed mutants was as effective as the wild-type HPV16 E7 protein in targeting pRb for degradation (Fig. 2B). The only mutant that was unable to induce pRb
degradation was del21-24, which cannot associate with pRb via
the LxCxE motif located in CR2. This is most consistent with a
previous report that even mutants with substantial deletions in
CR3 were still able to destabilize pRb (35).
The ability of all of the CR3 mutants to degrade pRb was unexpected, as this region is necessary for interaction with the cullin
2 E3 ubiquitin ligase which facilitates ubiquitination of pRb and
subsequent proteasome-mediated degradation (36, 53). In agreement with other studies, we show that CR3 confers association
with cullin 2 (Fig. 3A). Our finding that mutations in the zinccoordinating cysteine residues of CR3 still bind cullin 2 suggests
that this interaction occurs independently of the correct folding of
CR3, perhaps via a linear interaction motif. Although some CR3
mutations result in reduced binding capacity for cullin 2, these
mutants still degrade pRb as efficiently as wild-type E7 under nonsaturating conditions. We found this to be the case in the Saos2
degradation assay as well as in cells in which cullin 2 levels were
diminished by stable expression of a short hairpin RNA targeting
cullin 2. This suggests that a cullin 2-independent mechanism is
utilized for pRb degradation. This is certainly possible, as the ability of HPV16 E7 to bind cullin 2 is not shared by the E7 proteins of
any other HPV type so far tested (53).
Nearly 20 years ago, it was suggested that CR3 also functions as
a secondary lower affinity binding site for pRb (46). However, this
interaction was only recently confirmed by two independent re-

cells were transfected with the expression plasmid for the indicated E7 mutants
together with GFP, and 24 h posttransfection they were treated with cycloheximide for 15, 30, or 60 min. The levels of E7 were analyzed by Western blotting.
DMSO, dimethylsulfoxide.
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cotransfected with expression plasmids for HA epitope-tagged p21 and wildtype full-length E7 or the indicated mutant fused to a myc-GFP tag. Twentyfour h posttransfection, the cells were lysed and immunoprecipitation was
performed with anti-GFP antibody, followed by Western blotting.
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(Fig. 9), but it is possible that it has lost the capacity to interact
with another important cellular target which is necessary for E7 to
drive the cells into the S phase of the cell cycle.
Taken together, we have identified a new surface of HPV16 E7
that contributes to binding to pRb, which we have called patch 1.
We also observed that negative charges located in patch 2 likely
contribute to electrostatic interactions with pRb. Our data illustrate for the first time that the ability of E7 to bind pRb via CR3 is
important in overcoming the cell cycle arrest functions of pRb. In
light of these findings, we suggest that the CR3 domain of E7 is a
candidate for targeted inactivation by small-molecule compounds. Specifically, development of small molecules that bind
patch 1 of CR3 may disrupt the ability of E7 to perturb pRb function and have utility in the treatment of papillomas or HPV-induced cancers.
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